NasdaqCM - Nasdaq Real Time Price USD

Alterity Therapeutics Limited (ATHE)

Compare

3.5000

+0.1400

+(4.17%)

At close: 4:00:00 PM EDT

3.4999

-0.00

(-0.00%)

After hours: 4:07:07 PM EDT

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions – MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new presentations related to its Multiple System Atrophy (MSA)

GlobeNewswire 7 days ago

ATHE
+4.17%
PRNAF
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an oral presentation and a poster presentation related to Alterity’s clinical programs in Multiple System Atrophy (MSA) will be delivered at the American Academy of Neurology (AAN) 2025 Annual Meeting taking place Apr

GlobeNewswire 14 days ago

ATHE
+4.17%
PRNAF
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an

GlobeNewswire 21 days ago

ATHE
+4.17%
PRNAF
3 Promising ASX Penny Stocks With Market Caps Over A$20M

As Australian shares brace for a potential downturn, with the ASX 200 futures indicating a significant drop, investors are keenly observing market movements and their implications. In such volatile times, penny stocks—though an older term—remain relevant as they often represent smaller or emerging companies that could offer value. By focusing on those with strong financials and growth potential, investors might uncover opportunities in these lesser-known stocks.

Simply Wall St. last month

ATHE
+4.17%
PRNAF

VMT.AX
Alterity Therapeutics (ATHE): Among the Best Australian Stocks to Buy According to Billionaires

We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alterity Therapeutics Limited (NASDAQ:ATHE) stands against other best Australian stocks to buy according to billionaires. Australian Market Outlook 2025 In December 2024, Ausbil Investment Management Limited released its […]

Insider Monkey last month

ATH.AX
Alterity Therapeutics Raises A$40.0 million in Placement

– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, Australia and SAN FRANCISCO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or the “Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments

GlobeNewswire 2 months ago

ATHE
+4.17%
PRNAF
Alterity Therapeutics (ASX:ATH) shareholder returns have been stellar, earning 260% in 1 year

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

Simply Wall St. 2 months ago

ATHE
+4.17%
PRNAF
Top Midday Gainers

Alpha Modus (AMOD) Chief Executive William Alessi emphasized Thursday the company's "strong" fundame

PREMIUM
MT Newswires 2 months ago

ATH.AX
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions – – ATH434 Demonstrated a Favorable Safety Profile – – Webcast Held Yesterday with Access to the Recording Below – MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterit

GlobeNewswire 2 months ago

ATHE
+4.17%
PRNAF
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025ATH434-201 trial in early-stage MSA completed in November 2024Positive interim data presented at MDS from the ATH434-202 Phase 2 trial in advanced MSAMultiple data presentations and publications showing the potential for ATH434 to modify disease progression in neurodegenerative conditionsCash balance on 31 December 2024 of A$4.54 m MELBOURNE, Australia and SA

GlobeNewswire 2 months ago

ATHE
+4.17%
PRNAF
Alterity CEO says ‘filled with optimism for 2025’

Alterity Therapeutics (ATHE) issued a letter to shareholders from CEO David Stamler, stating in part: “As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity Therapeutics… 2024 was a year of significant progress for Alterity. Most prominently, we completed our 12-month, double-blind Phase 2 clinical trial of ATH434 in early-stage Multiple System Atrophy. This milestone leads us to a topline data readout expected in late January or early February. Last J

TipRanks 3 months ago

ATHE
+4.17%
PRNAF
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders. Dear Valued Shareholders: As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity Therapeutics. I want to express my sincere gratitude for your unwavering sup

GlobeNewswire 3 months ago

ATHE
+4.17%
PRNAF
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last patient in the ATH434-201 Phase 2 trial, a randomized, doub

GlobeNewswire 4 months ago

ATHE
+4.17%
PRNAF
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), has announced the appointment of Abby Macnish Niven as Alterity’s Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024. The Board and Management of Alterity thank Phillip for his valuable contributions over the

GlobeNewswire 4 months ago

ATHE
+4.17%
PRNAF
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history study at the 35th International Symposium on the Autonomic Nervous System. “The data presented highligh

GlobeNewswire 5 months ago

ATHE
+4.17%
PRNAF
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –MELBOURNE, AUSTRALIA and SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the peer-reviewed journal, Metallomics has published data on the importance of iron and iron-targeting agents like ATH434 to treat neurodeg

GlobeNewswire 5 months ago

ATHE
+4.17%
PRNAF
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025Positive interim data reported from ATH434-202 Phase 2 clinical trial showing the potential for ATH434 to modify disease progression in Multiple System AtrophyMultiple data presentations at the International Congress of Parkinson’s Disease and Movement Disorders® (MDS)Appointed Abby Macnish Niven as Chief Financial OfficerCash balance on 30 September 2024 of A$9.28m MELBOURN

GlobeNewswire 5 months ago

ATHE
+4.17%
PRNAF
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, 17 October 2024 at 1:30 p.m. ET in the United States / Friday, 18 Oc

GlobeNewswire 5 months ago

ATHE
+4.17%
PRNAF
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 were presented at the Society for Neuroscience 2024 in Chicago, USA. The poster entitled, “Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuc

GlobeNewswire 6 months ago

ATHE
+4.17%
PRNAF
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders - MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presenta

GlobeNewswire 6 months ago

ATHE
+4.17%
PRNAF

Performance Overview

Return	ATHE	S&P/ASX 200 [XJO] (^AXJO)
YTD	+5.74%	-4.17%
1-Year	+74.13%	+2.81%
3-Year	-55.13%	+3.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alterity Therapeutics Limited (ATHE)

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

3 Promising ASX Penny Stocks With Market Caps Over A$20M

Alterity Therapeutics (ATHE): Among the Best Australian Stocks to Buy According to Billionaires

Alterity Therapeutics Raises A$40.0 million in Placement

Alterity Therapeutics (ASX:ATH) shareholder returns have been stellar, earning 260% in 1 year

Top Midday Gainers

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Alterity CEO says ‘filled with optimism for 2025’

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

Performance Overview